News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The contract manufacturing sector lagged behind the rest of the outsourcing industry serving the pharmaceutical sector in 2004, but there are encouraging signs for the future, reports Phil Taylor.
Researchers in the US have found that blocking the COX-1, not COX-2 enzyme, might lead the way to prevent and treat the most common and fatal form of ovarian cancer.
Celera Genomics have filed an Investigational New Drug (IND) application for a novel histone deacetylase (HDAC) inhibitor that has proved effective in inhibiting cancer cell proliferation. The filing also signifies Celera's transformation from selling...